BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000;31:1019-21. [DOI: 10.1053/he.2000.6959] [Cited by in Crossref: 137] [Cited by in F6Publishing: 136] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Mulcahy MF. Management of hepatocellular cancer. Curr Treat Options Oncol. 2005;6:423-435. [PMID: 16107245 DOI: 10.1007/s11864-005-0045-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
2 Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, Durazo F, Saab S, Han S, Finn R, Hiatt JR, Busuttil RW. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005;41:1130-1137. [PMID: 15841454 DOI: 10.1002/hep.20688] [Cited by in Crossref: 244] [Cited by in F6Publishing: 227] [Article Influence: 14.4] [Reference Citation Analysis]
3 Katz AW, Chawla S, Qu Z, Kashyap R, Milano MT, Hezel AF. Stereotactic Hypofractionated Radiation Therapy as a Bridge to Transplantation for Hepatocellular Carcinoma: Clinical Outcome and Pathologic Correlation. International Journal of Radiation Oncology*Biology*Physics 2012;83:895-900. [DOI: 10.1016/j.ijrobp.2011.08.032] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 6.5] [Reference Citation Analysis]
4 Liu H, Liu J. Non-surgical treatment of primary hepatic carcinoma. Shijie Huaren Xiaohua Zazhi 2010; 18(24): 2563-2568 [DOI: 10.11569/wcjd.v18.i24.2563] [Reference Citation Analysis]
5 Llovet JM. Evidence-based medicine in the treatment of hepatocellular carcinoma: Evidence-based treatment of HCC. Journal of Gastroenterology and Hepatology 2002;17:S428-33. [DOI: 10.1046/j.1440-1746.17.s3.40.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
6 Welker MW, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge. Transpl Int. 2013;26:109-118. [PMID: 22994652 DOI: 10.1111/j.1432-2277.2012.01562.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 81] [Article Influence: 9.0] [Reference Citation Analysis]
7 Jelic S, Sotiropoulos GC; ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v59-v64. [PMID: 20555104 DOI: 10.1093/annonc/mdq166] [Cited by in Crossref: 121] [Cited by in F6Publishing: 126] [Article Influence: 10.1] [Reference Citation Analysis]
8 Thia TJK, Lui HF, Ooi LL, Chung YF, Chow PK, Cheow PC, Tan YM, Chow WC. A Study Into the Risk of Exacerbation of Chronic Hepatitis B After Liver Resection for Hepatocellular Carcinoma. J Gastrointest Surg 2007;11:612-8. [DOI: 10.1007/s11605-007-0121-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
9 Facciuto ME, Rochon C, Pandey M, Rodriguez-Davalos M, Samaniego S, Wolf DC, Kim-Schluger L, Rozenblit G, Sheiner PA. Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and outwith Milan criteria. HPB (Oxford) 2009;11:398-404. [PMID: 19768144 DOI: 10.1111/j.1477-2574.2009.00073.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Fukumoto T, Tominaga M, Kido M, Takebe A, Tanaka M, Kuramitsu K, Matsumoto I, Ajiki T, Ku Y. Long-term outcomes and prognostic factors with reductive hepatectomy and sequential percutaneous isolated hepatic perfusion for multiple bilobar hepatocellular carcinoma. Ann Surg Oncol. 2014;21:971-978. [PMID: 24201744 DOI: 10.1245/s10434-013-3305-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
11 Roayaie S, Llovet JM. Liver Transplantation for Hepatocellular Carcinoma: Is Expansion of Criteria Justified? Clinics in Liver Disease 2005;9:315-28. [DOI: 10.1016/j.cld.2004.12.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
12 Facciuto ME, Koneru B, Rocca JP, Wolf DC, Kim-Schluger L, Visintainer P, Klein KM, Chun H, Marvin M, Rozenblit G. Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation. Ann Surg Oncol. 2008;15:1383-1391. [PMID: 18320284 DOI: 10.1245/s10434-008-9851-z] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 3.9] [Reference Citation Analysis]
13 Huang W, Cui X, Chen Y, Shao M, Shao X, Shen Y, Liu Q, Wu M, Liu J, Ni W, Lu C, Wan C. High VRK1 expression contributes to cell proliferation and survival in hepatocellular carcinoma. Pathol Res Pract 2016;212:171-8. [PMID: 26706601 DOI: 10.1016/j.prp.2015.11.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
14 Facciuto ME, Singh MK, Katta U, Samaniego S, Sharma J, Rodriguez-davalos M, Sheiner P, Kim-schluger L, Wolf DC. Liver Transplantation for Hepatocellular Carcinoma: Defining the Impact of Using Extended Criteria Liver Allografts. Transplantation 2011;92:446-52. [DOI: 10.1097/tp.0b013e3182252733] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
15 Lombardi G, Zustovich F, Farinati F, Cillo U, Vitale A, Zanus G, Donach M, Farina M, Zovato S, Pastorelli D. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: Results of a phase 2 study. Cancer 2011;117:125-33. [DOI: 10.1002/cncr.25578] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
16 Daneker GW Jr, Staley CA. Surgical resection of hepatic tumors-patient selection and technical considerations. Cancer Treat Res 2001;109:229-46. [PMID: 11775439 DOI: 10.1007/978-1-4757-3371-6_13] [Reference Citation Analysis]
17 Ranchal I, González R, Bello RI, Ferrín G, Hidalgo AB, Linares CI, Aguilar-Melero P, González-Rubio S, Barrera P, Marchal T, Nakayama KI, de la Mata M, Muntané J. The reduction of cell death and proliferation by p27(Kip1) minimizes DNA damage in an experimental model of genotoxicity. Int J Cancer 2009;125:2270-80. [PMID: 19672859 DOI: 10.1002/ijc.24621] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
18 Liu M, Dong WG. Progress in non-surgical treatment of primary hepatic carcinoma. Shijie Huaren Xiaohua Zazhi 2009; 17(12): 1224-1228 [DOI: 10.11569/wcjd.v17.i12.1224] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
19 Shim JH, Park J, Nam BH, Lee WJ, Kim C. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009;63:459-67. [DOI: 10.1007/s00280-008-0759-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
20 Manga YB, Ko F, Yang Y, Hung J, Yang W, Huang H, Wu C. Ultra-fast and sensitive silicon nanobelt field-effect transistor for high-throughput screening of alpha-fetoprotein. Sensors and Actuators B: Chemical 2018;256:1114-21. [DOI: 10.1016/j.snb.2017.10.007] [Cited by in Crossref: 8] [Article Influence: 2.0] [Reference Citation Analysis]
21 Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7:350-391. [PMID: 19406039 DOI: 10.6004/jnccn.2009.0027] [Cited by in Crossref: 299] [Cited by in F6Publishing: 324] [Article Influence: 23.0] [Reference Citation Analysis]
22 Broelsch CE, Frilling A, Malago M. Hepatoma—resection or transplantation. Surgical Clinics of North America 2004;84:495-511. [DOI: 10.1016/j.suc.2003.11.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
23 Ferreira MV, Chaib E, Nascimento MU, Nersessian RS, Setuguti DT, D'Albuquerque LA. Liver transplantation and expanded Milan criteria: does it really work? Arq Gastroenterol 2012;49:189-94. [PMID: 23011240 DOI: 10.1590/s0004-28032012000300004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl. 2007;13:391-399. [PMID: 17318865 DOI: 10.1002/lt.21095] [Cited by in Crossref: 142] [Cited by in F6Publishing: 124] [Article Influence: 9.5] [Reference Citation Analysis]
25 Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. The Lancet Oncology 2004;5:409-18. [DOI: 10.1016/s1470-2045(04)01508-6] [Cited by in Crossref: 117] [Cited by in F6Publishing: 44] [Article Influence: 6.5] [Reference Citation Analysis]
26 Castells L, Allende E, Margarit C, Hidalgo E, Charco R, Cura D, Bilbao I, Lázaro J, Murio J. Mejoría de los resultados de la resección quirúrgica del hepatocarcinoma. Gastroenterología y Hepatología 2001;24:465-72. [DOI: 10.1016/s0210-5705(01)70216-6] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
27 Au KP, Chan SC, Chok KS, Chan AC, Cheung TT, Ng KK, Lo CM. Child-Pugh Parameters and Platelet Count as an Alternative to ICG Test for Assessing Liver Function for Major Hepatectomy. HPB Surg 2017;2017:2948030. [PMID: 28951631 DOI: 10.1155/2017/2948030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
28 Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543-1554. [PMID: 17133492 DOI: 10.1002/hep.21415] [Cited by in Crossref: 252] [Cited by in F6Publishing: 243] [Article Influence: 16.8] [Reference Citation Analysis]
29 Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524. [PMID: 11870363 DOI: 10.1053/jhep.2002.32089] [Cited by in Crossref: 801] [Cited by in F6Publishing: 753] [Article Influence: 40.1] [Reference Citation Analysis]
30 Facciuto ME, Rochon C, Pandey M, Rodriguez-Davalos M, Samaniego S, Wolf DC, Kim-Schluger L, Rozenblit G, Sheiner PA. Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and outwith Milan criteria. HPB (Oxford) 2009;11:398-404. [PMID: 19768144 DOI: 10.1111/j.1477-2574.2009.00073.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
31 Taura K, Ikai I, Hatano E, Yasuchika K, Nakajima A, Tada M, Seo S, Machimoto T, Uemoto S. Influence of coexisting cirrhosis on outcomes after partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: an analysis of 293 patients. Surgery. 2007;142:685-694. [PMID: 17981188 DOI: 10.1016/j.surg.2007.05.009] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 5.0] [Reference Citation Analysis]
32 Christians KK, Pitt HA, Rilling WS, Franco J, Quiroz FA, Adams MB, Wallace JR, Quebbeman EJ. Hepatocellular carcinoma: Multimodality management. Surgery 2001;130:554-60. [DOI: 10.1067/msy.2001.117106] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
33 Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009;249:799-805. [PMID: 19387322 DOI: 10.1097/sla.0b013e3181a38eb5] [Cited by in Crossref: 185] [Cited by in F6Publishing: 78] [Article Influence: 14.2] [Reference Citation Analysis]
34 Steinmüller T, Pascher A, Sauer I, Theruvath T, Müller A, Settmacher U, Neuhaus P. Living-donation liver transplantation for hepatocellular carcinoma: time to drop the limitations? Transplantation Proceedings 2002;34:2263-4. [DOI: 10.1016/s0041-1345(02)03228-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Li Y, Ruan D, Yi H, Wang G, Yang Y, Jiang N. A three-factor preoperative scoring model predicts risk of recurrence after liver resection or transplantation in hepatocellular carcinoma patients with preserved liver function. Hepatobiliary & Pancreatic Diseases International 2015;14:477-84. [DOI: 10.1016/s1499-3872(15)60412-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
36 Baba HA, Wohlschlaeger J, Cicinnati VR, Hilgard P, Lang H, Sotiropoulos GC, Takeda A, Beckebaum S, Schmitz KJ. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma. Liver Int. 2009;29:399-405. [PMID: 18492014 DOI: 10.1111/j.1478-3231.2008.01798.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
37 Duffy JP, Hiatt JR, Busuttil RW. Surgical resection of hepatocellular carcinoma. Cancer J. 2008;14:100-110. [PMID: 18391615 DOI: 10.1097/ppo.0b013e31816a5c1f] [Cited by in Crossref: 39] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
38 Scatton O, Zalinski S, Terris B, Lefevre JH, Casali A, Massault PP, Conti F, Calmus Y, Soubrane O. Hepatocellular carcinoma developed on compensated cirrhosis: resection as a selection tool for liver transplantation. Liver Transpl. 2008;14:779-788. [PMID: 18508370 DOI: 10.1002/lt.21431] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
39 Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430. [PMID: 11592607 DOI: 10.1016/s0168-8278(01)00130-1] [Cited by in Crossref: 3112] [Cited by in F6Publishing: 1064] [Article Influence: 155.6] [Reference Citation Analysis]
40 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 27] [Article Influence: 0.5] [Reference Citation Analysis]
41 Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg. 2001;233:652-659. [PMID: 11323504 DOI: 10.1097/00000658-200105000-00009] [Cited by in Crossref: 241] [Cited by in F6Publishing: 219] [Article Influence: 11.5] [Reference Citation Analysis]
42 Patt CH, Thuluvath PJ. Role of Liver Transplantation in the Management of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2002;13:S205-10. [DOI: 10.1016/s1051-0443(07)61788-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
43 Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K, Kawamura T, Teramoto K, Arii S. Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting milan criteria: Rationale for partial hepatectomy as first strategy. J Am Coll Surg. 2007;204:1-6. [PMID: 17189106 DOI: 10.1016/j.jamcollsurg.2006.10.004] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 3.5] [Reference Citation Analysis]
44 Margarit C, Escartín A, Castells L, Vargas V, Allende E, Bilbao I. Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl 2005;11:1242-51. [DOI: 10.1002/lt.20398] [Cited by in Crossref: 154] [Cited by in F6Publishing: 144] [Article Influence: 9.1] [Reference Citation Analysis]
45 Newell AM, Yousef GG, Lila MA, Ramírez-mares MV, Gonzalez de Mejia E. Comparative in vitro bioactivities of tea extracts from six species of Ardisia and their effect on growth inhibition of HepG2 cells. Journal of Ethnopharmacology 2010;130:536-44. [DOI: 10.1016/j.jep.2010.05.051] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
46 Qiao G, Li J, Huang A, Yan Z, Lau WY, Shen F. Artificial neural networking model for the prediction of post-hepatectomy survival of patients with early hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:2014-2020. [PMID: 24989634 DOI: 10.1111/jgh.12672] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
47 Marsh JW, Dvorchik I. Liver organ allocation for hepatocellular carcinoma: are we sure? Liver Transpl. 2003;9:693-696. [PMID: 12827554 DOI: 10.1053/jlts.2003.50086] [Cited by in Crossref: 97] [Cited by in F6Publishing: 88] [Article Influence: 5.1] [Reference Citation Analysis]
48 Li L, Zhao GD, Shi Z, Qi LL, Zhou LY, Fu ZX. The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncol Lett 2016;12:3045-50. [PMID: 27899961 DOI: 10.3892/ol.2016.5110] [Cited by in Crossref: 113] [Cited by in F6Publishing: 106] [Article Influence: 18.8] [Reference Citation Analysis]
49 Chu JS, Ge FJ, Zhang B, Wang Y, Silvestris N, Liu LJ, Zhao CH, Lin L, Brunetti AE, Fu YL, Wang J, Paradiso A, Xu JM. Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res 2013;32:16. [PMID: 23552472 DOI: 10.1186/1756-9966-32-16] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 6.6] [Reference Citation Analysis]
50 Shim JH, Park JW, Choi JI, Kim HB, Lee WJ, Kim CM. Does postembolization fever after chemoembolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma? J Vasc Interv Radiol. 2009;20:209-216. [PMID: 19084432 DOI: 10.1016/j.jvir.2008.10.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
51 Lorenzo GD, Rea A, Carlomagno C, Pepe S, Palmieri G, Labianca R, Chirianni A, Stefano AD, Esposito V, Placido SD, Montesarchio V. Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study. World J Gastroenterol 2007; 13(48): 6553-6557 [PMID: 18161926 DOI: 10.3748/wjg.v13.i48.6553] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
52 Sauer P, Kraus TW, Schemmer P, Mehrabi A, Stremmel W, Buechler MW, Encke J. Liver Transplantation for Hepatocellular Carcinoma: Is there Evidence for Expanding the Selection Criteria? Transplantation 2005;80:S105-8. [DOI: 10.1097/01.tp.0000187107.64215.7b] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
53 Soliman T, Berlakovich GA, Mühlbacher F, Steininger R. Liver transplantation for hepatic malignancies. Eur Surg 2006;38:63-8. [DOI: 10.1007/s10353-005-0208-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Lin ZZ, Hsu C, Hu FC, Shao YY, Chang DY, Yang CH, Hong RL, Hsu CH, Cheng AL. Factors impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy. Oncologist. 2012;17:970-977. [PMID: 22673633 DOI: 10.1634/theoncologist.2011-0411] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
55 Stadlbauer V, Schaffellner S, Kniepeiss D, Jakoby E, Stauber R, Iberer F, Tscheliessnigg KH. Experiences in liver transplantation for hepatocellular carcinoma. Transplant Proc 2004;36:195-8. [PMID: 15013344 DOI: 10.1016/j.transproceed.2003.11.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
56 Richly H, Schultheis B, Adamietz IA, Kupsch P, Grubert M, Hilger RA, Ludwig M, Brendel E, Christensen O, Strumberg D. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer. 2009;45:579-587. [PMID: 19101137 DOI: 10.1016/j.ejca.2008.10.039] [Cited by in Crossref: 49] [Cited by in F6Publishing: 59] [Article Influence: 3.5] [Reference Citation Analysis]
57 Ahn J, Flamm SL. Hepatocellular carcinoma. Dis Mon 2004;50:556-73. [PMID: 15616490 DOI: 10.1016/j.disamonth.2004.10.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
58 Wang J, Wang FW. Refusal of cancer-directed surgery strongly impairs survival of patients with localized hepatocellular carcinoma. Int J Surg Oncol 2010;2010:381795. [PMID: 22312489 DOI: 10.1155/2010/381795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
59 Imvrios G, Papanikolaou V, Vrochides D, Ouzounidis N, Papagiannis A, Fouzas I, Giakoustidis D, Antoniades N, Iosifidou S, Patsiaoura K, Zafiriadou E, Takoudas D. Liver transplantation outcomes in patients with cirrhosis and hepatocellular carcinoma: experience of a single center in a viral hepatitis endemic area. Transplant Proc 2007;39:1508-10. [PMID: 17580174 DOI: 10.1016/j.transproceed.2006.12.039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
60 Kow AWC. Transplantation vs liver resection in patients with hepatocellular carcinoma. Transl Gastroenterol Hepatol. 2019;4:33. [PMID: 31231700 DOI: 10.21037/tgh.2019.05.06] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
61 Abou-alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard J, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. JCO 2006;24:4293-300. [DOI: 10.1200/jco.2005.01.3441] [Cited by in Crossref: 858] [Cited by in F6Publishing: 363] [Article Influence: 53.6] [Reference Citation Analysis]
62 Hong YJ, Kim SH, Choi GH, Kim KS, Choi JS. Long-term outcome after liver resection and clinicopathological features in patients with small hepatocellular carcinoma. Korean J Hepatobiliary Pancreat Surg 2011;15:199-205. [PMID: 26421040 DOI: 10.14701/kjhbps.2011.15.4.199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
63 Gournay J, Tchuenbou J, Richou C, Masliah C, Lerat F, Dupas B, Martin T, Nouel JF, Schnée M, Montigny P, D'alincourt A, Hamy A, Paineau J, Le Néel J-, Le Borgne J, Galmiche JP. Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: a retrospective case-control study with cost analysis: PERCUTANEOUS ETHANOL INJECTION VS. RESECTION IN HEPATOCELLULAR CARCINOMA. Alimentary Pharmacology & Therapeutics 2002;16:1529-38. [DOI: 10.1046/j.1365-2036.2002.01307.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
64 Delis SG, Bakoyiannis A, Tassopoulos N, Athanassiou K, Kechagias A, Kelekis D, Madariaga J, Dervenis C. Hepatic resection for large hepatocellular carcinoma in the era of UCSF criteria. HPB (Oxford) 2009;11:551-8. [PMID: 20495706 DOI: 10.1111/j.1477-2574.2009.00084.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
65 Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002;122:1609-1619. [PMID: 12016426 DOI: 10.1053/gast.2002.33411] [Cited by in Crossref: 374] [Cited by in F6Publishing: 363] [Article Influence: 18.7] [Reference Citation Analysis]
66 Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol 2013;19:7316-26. [PMID: 24259963 DOI: 10.3748/wjg.v19.i42.7316] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
67 Pan Y, Sun C, Huang M, Liu Y, Qi F, Liu L, Wen J, Liu J, Xie K, Ma H, Hu Z, Shen H. A genetic variant in pseudogene E2F3P1 contributes to prognosis of hepatocellular carcinoma. J Biomed Res 2014;28:194-200. [PMID: 25013402 DOI: 10.7555/JBR.28.20140052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
68 Bellavance EC, Lumpkins KM, Mentha G, Marques HP, Capussotti L, Pulitano C, Majno P, Mira P, Rubbia-brandt L, Ferrero A, Aldrighetti L, Cunningham S, Russolillo N, Philosophe B, Barroso E, Pawlik TM. Surgical Management of Early-Stage Hepatocellular Carcinoma: Resection or Transplantation? J Gastrointest Surg 2008;12:1699-708. [DOI: 10.1007/s11605-008-0652-2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 4.5] [Reference Citation Analysis]
69 Mathurin P, Raynard B, Dharancy S, Kirzin S, Fallik D, Pruvot F, Roumilhac D, Canva V, Paris J, Chaput J, Naveau S. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma: META-ANALYSIS: ADJUVANT THERAPY AFTER CURATIVE LIVER RESECTION FOR HCC. Alimentary Pharmacology & Therapeutics 2003;17:1247-61. [DOI: 10.1046/j.1365-2036.2003.01580.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 4.0] [Reference Citation Analysis]
70 Lei JY, Wang WT, Yan LN. Hangzhou criteria for liver transplantation in hepatocellular carcinoma: a single-center experience. European Journal of Gastroenterology & Hepatology 2014;26:200-4. [DOI: 10.1097/meg.0b013e3283652b66] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
71 Vivanco M, Gabrielli M, Jarufe N, Humeres R, Rios H, Palacios JM, Zapata R, Sanhueza E, Contreras J, Rencore G, Rossi R, Martínez J, Pérez R, Guerra J, Arrese M, Figueroa E, Soza A, Yáñes R, Hepp J. Bridge therapy in hepatocellular carcinoma before liver transplantation: the experience of two Chilean centers. Transplant Proc 2010;42:296-8. [PMID: 20172335 DOI: 10.1016/j.transproceed.2009.11.019] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
72 Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, Rodés J, Bruix J. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut. 2002;50:123-128. [PMID: 11772979 DOI: 10.1136/gut.50.1.123] [Cited by in Crossref: 202] [Cited by in F6Publishing: 178] [Article Influence: 10.1] [Reference Citation Analysis]
73 Wu P, Guo L, Yu S, Zeng N, Liu Y, Yu J, Zhang Z, Lu K, Sun L, Wang C, Chang Y, Lu Y, Shen Y, Tai S, Chuang Y, Ho JA, Huang K, Wu Y, Liu T. Noninvasive assessment of liver function reserve with fluorescent dosimetry of indocyanine green. Biomed Opt Express 2022;13:1995. [DOI: 10.1364/boe.446749] [Reference Citation Analysis]
74 Gabrielli M, Vivanco M, Hepp J, Martínez J, Pérez R, Guerra J, Arrese M, Figueroa E, Soza A, Yáñes R, Humeres R, Rios H, Palacios JM, Zapata R, Sanhueza E, Contreras J, Rencoret G, Rossi R, Jarufe N. Liver transplantation results for hepatocellular carcinoma in Chile. Transplant Proc 2010;42:299-301. [PMID: 20172336 DOI: 10.1016/j.transproceed.2009.11.034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
75 Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, Samuel D, Bismuth H. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: A reasonable strategy? Ann Surg. 2003;238:508-18; discussion 518-9. [PMID: 14530722 DOI: 10.1097/01.sla.0000090449.87109.44] [Cited by in Crossref: 66] [Cited by in F6Publishing: 131] [Article Influence: 3.5] [Reference Citation Analysis]
76 Donckier V, Van Laethem JL, Van Gansbeke D, Ickx B, Lingier P, Closset J, El Nakadi I, Feron P, Boon N, Bourgeois N, Adler M, Gelin M. New considerations for an overall approach to treat hepatocellular carcinoma in cirrhotic patients. J Surg Oncol 2003;84:36-44. [DOI: 10.1002/jso.10281] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
77 Asham EH, Kaseb A, Ghobrial RM. Management of Hepatocellular Carcinoma. Surgical Clinics of North America 2013;93:1423-50. [DOI: 10.1016/j.suc.2013.08.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
78 Emond JC, Samstein B, Renz JF. A critical evaluation of hepatic resection in cirrhosis: optimizing patient selection and outcomes. World J Surg. 2005;29:124-130. [PMID: 15654659 DOI: 10.1007/s00268-004-7633-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
79 Cucchetti A, Cescon M, Ercolani G, Morelli MC, Del Gaudio M, Zanello M, Pinna AD. Comparison between observed survival after resection of transplantable hepatocellular carcinoma and predicted survival after listing through a Markov model simulation. Transpl Int 2011;24:787-96. [PMID: 21615549 DOI: 10.1111/j.1432-2277.2011.01276.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
80 Perry JF, Charlton B, Koorey DJ, Waugh RC, Gallagher PJ, Crawford MD, Verran DJ, McCaughan GW, Strasser SI. Outcome of patients with hepatocellular carcinoma referred to a tertiary centre with availability of multiple treatment options including cadaveric liver transplantation. Liver Int. 2007;27:1240-1248. [PMID: 17919236 DOI: 10.1111/j.1478-3231.2007.01569.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
81 Llovet JM, Vilana R, Bianchi L, Brú C. [Radiofrequency in the treatment of hepatocellular carcinoma]. Gastroenterol Hepatol 2001;24:303-11. [PMID: 11459568 DOI: 10.1016/s0210-5705(01)70180-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
82 Llovet JM, Bruix J. Early diagnosis and treatment of hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol 2000;14:991-1008. [PMID: 11139351 DOI: 10.1053/bega.2000.0143] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 1.6] [Reference Citation Analysis]
83 Nakayama H, Sugahara S, Tokita M, Fukuda K, Mizumoto M, Abei M, Shoda J, Sakurai H, Tsuboi K, Tokuuye K. Proton beam therapy for hepatocellular carcinoma: the University of Tsukuba experience. Cancer. 2009;115:5499-5506. [PMID: 19645024 DOI: 10.1002/cncr.24619] [Cited by in Crossref: 89] [Cited by in F6Publishing: 71] [Article Influence: 7.4] [Reference Citation Analysis]
84 Fernández JA, Robles R, Marin C, Sánchez-Bueno F, Ramirez P, Pons JA, Garre MC, Pérez D, Parrilla A, Navalón JC, Parrilla P. Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size? Transplant Proc 2003;35:1818-20. [PMID: 12962807 DOI: 10.1016/s0041-1345(03)00723-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
85 Bonder A, Afdhal N. Evaluation of liver lesions. Clin Liver Dis 2012;16:271-83. [PMID: 22541698 DOI: 10.1016/j.cld.2012.03.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
86 Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol. 2003;21:4329-4335. [PMID: 14581446 DOI: 10.1200/jco.2003.11.137] [Cited by in Crossref: 181] [Cited by in F6Publishing: 45] [Article Influence: 9.5] [Reference Citation Analysis]
87 Qian MY, Yuwei J R, Angus P, Schelleman T, Johnson L, Gow P. Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital. J Gastroenterol Hepatol. 2010;25:951-956. [PMID: 20546449 DOI: 10.1111/j.1440-1746.2009.06203.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
88 Ramos E, Lladó L, Serrano T, Figueras A, Lastra R, Torras J, Figueras J, Rafecas A, Fabregat J. Utility of Cell-cycle Modulators to Predict Vascular Invasion and Recurrence After Surgical Treatment of Hepatocellular Carcinoma. Transplantation 2006;82:753-8. [DOI: 10.1097/01.tp.0000234718.40266.75] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
89 Jun CH, Ki HS, Lee HK, Park KJ, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK, Rew JS. Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma. World J Gastroenterol 2013; 19(2): 284-289 [PMID: 23345952 DOI: 10.3748/wjg.v19.i2.284] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
90 Eghtesad B, Aucejo F. Liver transplantation for malignancies. J Gastrointest Cancer. 2014;45:353-362. [PMID: 24604263 DOI: 10.1007/s12029-014-9590-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
91 Hassoun Z, Gores GJ. Treatment of hepatocellular carcinoma. Clinical Gastroenterology and Hepatology 2003;1:10-8. [DOI: 10.1053/jcgh.2003.50003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
92 Puneet P, Perera MTPR, Mirza DF. Current opinion on the role of resection and liver transplantation for hepatocellular cancer. Indian J Gastroenterol 2012;31:89-99. [DOI: 10.1007/s12664-012-0200-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
93 Kim Y, Hwang J, Kwon H, Lee W, Song H, Jeong J, Sung S, Moon S, Jeon B, Park P. n-butanol fraction of Uncaria rhynchophylla induces apoptosis in human hepatoma cancer cells through activation of PARP. Biotechnol Bioproc E 2014;19:411-8. [DOI: 10.1007/s12257-013-0644-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
94 Adam R. Improvement of survival by surgery in the treatment of hepatocellular carcinoma: evidence or non-evidenced-based? Ann Surg Oncol 2004;11:460-1. [PMID: 15078638 DOI: 10.1245/ASO.2004.02.911] [Reference Citation Analysis]
95 García-valdecasas J, Fuster J, Grande L, Fondevila C, Rimola A, Navasa M, Cirera I, Bombuy E, Visa J. Trasplante hepático en adulto de donante vivo. Resultados iniciales. Gastroenterología y Hepatología 2001;24:275-80. [DOI: 10.1016/s0210-5705(01)70174-4] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
96 Lin ZZ, Hsu HC, Hsu CH, Yeh PY, Huang CY, Huang YF, Chen TJ, Kuo SH, Hsu C, Hu FC, Jeng YM, Chung Y, Cheng AL. The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J Hepatol 2009;50:518-27. [PMID: 19155085 DOI: 10.1016/j.jhep.2008.10.022] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
97 Cucchetti A, Piscaglia F, Caturelli E, Benvegnù L, Vivarelli M, Ercolani G, Cescon M, Ravaioli M, Grazi GL, Bolondi L. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol. 2009;16:413-422. [PMID: 19034578 DOI: 10.1245/s10434-008-0232-4] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 7.9] [Reference Citation Analysis]
98 Bharat A, Brown DB, Crippin JS, Gould JE, Lowell JA, Shenoy S, Desai NM, Chapman WC. Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg. 2006;203:411-420. [PMID: 17000383 DOI: 10.1016/j.jamcollsurg.2006.06.016] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 5.8] [Reference Citation Analysis]
99 Komatsu S, Murakami M, Fukumoto T, Hori Y, Hishikawa Y, Ku Y. Risk factors for survival and local recurrence after particle radiotherapy for single small hepatocellular carcinoma. Br J Surg. 2011;98:558-564. [PMID: 21246516 DOI: 10.1002/bjs.7397] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
100 Sherman M. Screening for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19:101-118. [PMID: 15757807 DOI: 10.1016/j.bpg.2004.11.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
101 Benzoni E, Lorenzin D, Favero A, Adani G, Baccarani U, Molaro R, Zompicchiatti A, Saccomano E, Avellini C, Bresadola F, Uzzau A. Liver Resection for Hepatocellular Carcinoma: a Multivariate Analysis of Factors Associated with Improved Prognosis. the Role of Clinical, Pathological and Surgical Related Factors. Tumori 2007;93:264-8. [DOI: 10.1177/030089160709300306] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
102 Moon D, Lee S, Hwang S. Liver Transplantation for Hepatocellular Carcinoma: Single Nodule with Child-Pugh Class A Sized Less than 3 cm. Dig Dis 2007;25:320-8. [DOI: 10.1159/000106912] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
103 Bruix J, Sherman M;  Practice Guidelines Committee;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. [PMID: 16250051 DOI: 10.1002/hep.20933] [Cited by in Crossref: 4104] [Cited by in F6Publishing: 3893] [Article Influence: 241.4] [Reference Citation Analysis]
104 Venkat R, Hannallah JR, Krouse RS, Maegawa FB. Preoperative thrombocytopenia and outcomes of hepatectomy for hepatocellular carcinoma. Journal of Surgical Research 2016;201:498-505. [DOI: 10.1016/j.jss.2015.08.038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
105 Gaiani S, Celli N, Cecilioni L, Piscaglia F, Bolondi L. Percutaneous treatment of hepatocellular carcinoma: REVIEW: PERCUTANEOUS TREATMENT OF HEPATOCELLULAR CARCINOMA. Alimentary Pharmacology & Therapeutics 2003;17:103-10. [DOI: 10.1046/j.1365-2036.17.s2.21.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
106 Harimoto N, Yoshizumi T, Fujimoto Y, Motomura T, Mano Y, Toshima T, Itoh S, Harada N, Ikegami T, Uchiyama H, Soejima Y, Maehara Y. Surgery for Hepatocellular Carcinoma in Patients with Child–Pugh B Cirrhosis: Hepatic Resection Versus Living Donor Liver Transplantation. World J Surg 2018;42:2606-16. [DOI: 10.1007/s00268-018-4493-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
107 Onaca N, Davis GL, Jennings LW, Goldstein RM, Klintmalm GB. Improved results of transplantation for hepatocellular carcinoma: A report from the international registry of hepatic tumors in liver transplantation. Liver Transpl 2009;15:574-80. [DOI: 10.1002/lt.21738] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
108 Zhuang X, Wang Q, Wang N, Hou X, Zhang J, Chi H. Effects of combining transarterial chemoembolization with percutaneous microwave coagulation therapy for hepatocellular carcinoma abutting the diaphragm. Minim Invasive Ther Allied Technol 2016;25:107-12. [PMID: 26560859 DOI: 10.3109/13645706.2015.1103751] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
109 Marsh JW, Finkelstein SD, Demetris AJ, Swalsky PA, Sasatomi E, Bandos A, Subotin M, Dvorchik I. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl. 2003;9:664-671. [PMID: 12827550 DOI: 10.1053/jlts.2003.50144] [Cited by in Crossref: 104] [Cited by in F6Publishing: 89] [Article Influence: 5.5] [Reference Citation Analysis]
110 Thelen A, Scholz A, Benckert C, von Marschall Z, Schröder M, Wiedenmann B, Neuhaus P, Rosewicz S, Jonas S. VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma. Int J Cancer. 2008;122:2471-2481. [PMID: 18338756 DOI: 10.1002/ijc.23439] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
111 Sherman M. Screening for hepatocellular carcinoma. Hepatology Research 2007;37:S152-65. [DOI: 10.1111/j.1872-034x.2007.00180.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
112 Jansen PL. Liver disease in the elderly. Best Pract Res Clin Gastroenterol. 2002;16:149-158. [PMID: 11977934 DOI: 10.1053/bega.2002.0271] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
113 Shah SA, Cleary SP, Tan JC, Wei AC, Gallinger S, Grant DR, Greig PD. An analysis of resection vs transplantation for early hepatocellular carcinoma: defining the optimal therapy at a single institution. Ann Surg Oncol. 2007;14:2608-2614. [PMID: 17522942 DOI: 10.1245/s10434-007-9443-3] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 4.9] [Reference Citation Analysis]
114 Sherman M. Surveillance for hepatocellular carcinoma and early diagnosis. Clin Liver Dis. 2007;11:817-837, viii. [PMID: 17981230 DOI: 10.1016/j.cld.2007.08.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
115 Feng X, Pai M, Mizandari M, Chikovani T, Spalding D, Jiao L, Habib N. Towards the optimization of management of hepatocellular carcinoma. Front Med 2011;5:271-6. [DOI: 10.1007/s11684-011-0148-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
116 Freeman RB Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, Merion R, Wolfe R, Turcotte J, Teperman L;  UNOS/OPTN Liver Disease Severity Score; UNOS/OPTN Liver and Intestine;  and UNOS/OPTN Pediatric Transplantation Committees. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002;8:851-858. [PMID: 12200791 DOI: 10.1053/jlts.2002.35927] [Cited by in Crossref: 505] [Cited by in F6Publishing: 435] [Article Influence: 26.6] [Reference Citation Analysis]
117 Adam R, Del Gaudio M. Evolution of liver transplantation for hepatocellular carcinoma. J Hepatol. 2003;39:888-895. [PMID: 14642602 DOI: 10.1016/j.jhep.2003.10.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
118 Hou Y, Wang Z, Huang S, Sun C, Zhao J, Shi J, Li Z, Wang Z, He X, Tam NL, Wu L. SKA3 Promotes tumor growth by regulating CDK2/P53 phosphorylation in hepatocellular carcinoma. Cell Death Dis 2019;10:929. [PMID: 31804459 DOI: 10.1038/s41419-019-2163-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
119 Rust C, Gores GJ. Locoregional management of hepatocellular carcinoma. Surgical and ablation therapies. Clin Liver Dis. 2001;5:161-173. [PMID: 11218913 DOI: 10.1016/s1089-3261(05)70159-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
120 Kaibori M, Saito T, Matsui Y, Uchida Y, Ishizaki M, Kamiyama Y. A review of the prognostic factors in patients with recurrence after liver resection for hepatocellular carcinoma. Am J Surg 2007;193:431-7. [PMID: 17368283 DOI: 10.1016/j.amjsurg.2006.06.041] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
121 Kamarajah SK. Fibrosis score impacts survival following resection for hepatocellular carcinoma (HCC): A Surveillance, End Results and Epidemiology (SEER) database analysis. Asian Journal of Surgery 2018;41:551-61. [DOI: 10.1016/j.asjsur.2018.01.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
122 Simonetti RG, Gluud C, Pagliaro L; Cochrane Hepato-Biliary Group. Interferon for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2021;2021. [DOI: 10.1002/14651858.cd003883] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
123 Jelic S; ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:41-45. [PMID: 19454459 DOI: 10.1093/annonc/mdp124] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
124 Pingsheng F, Tengyue Z, Qiang H, Qiang W, Xin S, Liting Q. Basic and clinical research on the therapeutic effect of intervention in primary liver cancer by targeted intra-arterial verapamil infusion. Cell Biochem Biophys 2012;62:59-67. [PMID: 21830124 DOI: 10.1007/s12013-011-9259-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
125 Del Gaudio M, Ercolani G, Ravaioli M, Cescon M, Lauro A, Vivarelli M, Zanello M, Cucchetti A, Vetrone G, Tuci F. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant. 2008;8:1177-1185. [PMID: 18444925 DOI: 10.1111/j.1600-6143.2008.02229.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 118] [Article Influence: 8.1] [Reference Citation Analysis]
126 Xu X, Liu C, Qu K, Song Y, Zhang P, Zhang Y. Liver transplantation versus liver resection for hepatocellular carcinoma: a meta-analysis. Hepatobiliary & Pancreatic Diseases International 2014;13:234-41. [DOI: 10.1016/s1499-3872(14)60037-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
127 Itamoto T, Nakahara H, Tashiro H, Ohdan H, Hino H, Ochi M, Asahara T. Indications of partial hepatectomy for transplantable hepatocellular carcinoma with compensated cirrhosis. The American Journal of Surgery 2005;189:167-72. [DOI: 10.1016/j.amjsurg.2004.11.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
128 Nathan H, Mentha G, Marques HP, Capussotti L, Majno P, Aldrighetti L, Pulitano C, Rubbia-Brandt L, Russolillo N, Philosophe B, Barroso E, Ferrero A, Schulick RD, Choti MA, Pawlik TM. Comparative performances of staging systems for early hepatocellular carcinoma. HPB (Oxford) 2009;11:382-90. [PMID: 19768142 DOI: 10.1111/j.1477-2574.2009.00070.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
129 Mergental H, Adam R, Ericzon B, Kalicinski P, Mühlbacher F, Höckerstedt K, Klempnauer JL, Friman S, Broelsch CE, Mantion G, Fernandez-sellez C, van Hoek B, Fangmann J, Pirenne J, Muiesan P, Königsrainer A, Mirza DF, Lerut J, Detry O, Le Treut Y, Mazzaferro V, Löhe F, Berenguer M, Clavien P, Rogiers X, Belghiti J, Kóbori L, Burra P, Wolf P, Schareck W, Pisarski P, Foss A, Filipponi F, Krawczyk M, Wolff M, Langrehr JM, Rolles K, Jamieson N, Hop WC, Porte RJ. Liver transplantation for unresectable hepatocellular carcinoma in normal livers. Journal of Hepatology 2012;57:297-305. [DOI: 10.1016/j.jhep.2012.03.022] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
130 Gaiani S, Celli N, Cecilioni L, Piscaglia F, Bolondi L. Percutaneous treatment of hepatocellular carcinoma: REVIEW: PERCUTANEOUS TREATMENT OF HEPATOCELLULAR CARCINOMA. Alimentary Pharmacology & Therapeutics 2003;17:103-10. [DOI: 10.1046/j.1365-2036.17.s2.21.x] [78495111110.1046/j.1365-2036.17.s2.21.x','', '1948-5182')">Reference Citation Analysis]
131 Pazirandeh S, Khettry U, Gordon FD, Resnick RH, Murray JE, Sheth SG. Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States. Dig Dis Sci 2007;52:220-7. [PMID: 17160481 DOI: 10.1007/s10620-006-9184-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
132 Turner PM, Turner TJ. Validation of the crisis triage rating scale for psychiatric emergencies. Can J Psychiatry. 1991;36:651-654. [PMID: 1773400 DOI: 10.1136/gut.51.4.459] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 2.5] [Reference Citation Analysis]
133 Morihara D, Iwata K, Hanano T, Kunimoto H, Kuno S, Fukunaga A, Yotsumoto K, Takata K, Tanaka T, Sakurai K, Iwashita H, Ueda S, Hirano G, Yokoyama K, Nakane H, Nishizawa S, Yoshikane M, Anan A, Takeyama Y, Kakumitsu S, Kitamura Y, Sakamoto M, Irie M, Shakado S, Sohda T, Watanabe H, Sakisaka S. Late-evening snack with branched-chain amino acids improves liver function after radiofrequency ablation for hepatocellular carcinoma: LES with BCAA improves liver function. Hepatology Research 2012;42:658-67. [DOI: 10.1111/j.1872-034x.2012.00969.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
134 Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, Ramacciato G, Grazi GL, Pinna AD. Is portal hypertension a contraindication to hepatic resection? Ann Surg 2009;250:922-8. [PMID: 19855258 DOI: 10.1097/SLA.0b013e3181b977a5] [Cited by in Crossref: 150] [Cited by in F6Publishing: 58] [Article Influence: 12.5] [Reference Citation Analysis]
135 Bernal E, Montero J, Delgado M, Fraga E, Costán G, Barrera P, López-vallejos P, Solórzano G, Rufián S, Briceño J, Padillo J, López-cillero P, Marchal T, Muntané J, de la Mata M. Adjuvant Chemotherapy for Prevention of Recurrence of Invasive Hepatocellular Carcinoma After Orthotopic Liver Transplantation. Transplantation Proceedings 2006;38:2495-8. [DOI: 10.1016/j.transproceed.2006.08.053] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
136 Huang J, Duan Q, Fan P, Ji C, Lv Y, Lin X, Qian L, Yu X. Clinical evaluation of targeted arterial infusion of verapamil in the interventional chemotherapy of primary hepatocellular carcinoma. Cell Biochem Biophys 2011;59:127-32. [PMID: 20963512 DOI: 10.1007/s12013-010-9125-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
137 Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235:373-382. [PMID: 11882759 DOI: 10.1097/00000658-200203000-00009] [Cited by in Crossref: 596] [Cited by in F6Publishing: 584] [Article Influence: 29.8] [Reference Citation Analysis]
138 Hourmand-Ollivier I, Chiche L. [Treatment of hepatocellular carcinoma in the cirrhotic liver]. J Chir (Paris) 2004;141:71-83. [PMID: 15133430 DOI: 10.1016/s0021-7697(04)95574-3] [Reference Citation Analysis]
139 Sapisochin G, Sevilla EF, Echeverri J, Charco R. Management of “very early” hepatocellular carcinoma on cirrhotic patients. World J Hepatol 2014; 6(11): 766-775 [PMID: 25429314 DOI: 10.4254/wjh.v6.i11.766] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]